Vyriad Revolutionizes Cancer Care: $85M Fuels "One-Shot" In Vivo CAR T for Multiple Myeloma
December 25, 2025, 9:37 am
Vyriad closes an $85M Series B round. This fuels VV169, its groundbreaking in vivo CAR T-cell therapy. VV169 targets multiple myeloma, delivering a curative genetic payload via a single intravenous injection. This revolutionary approach bypasses the intricate, costly ex vivo lab manufacturing of traditional CAR T. It directly reprograms immune cells within the body. This significantly improves scalability and patient access. Robust preclinical data showed complete tumor eradication in models. Human trials are set for 2026. Vyriad aims to transform cancer therapy access and efficacy.
Vyriad secured substantial funding. The Rochester, Minnesota biotechnology firm closed an $85 million Series B round. This capital accelerates a radical shift in cancer treatment. Its focus: in vivo CAR T-cell therapy. This innovation aims to transform patient care for multiple myeloma.
Current CAR T therapies offer immense hope. They also present significant hurdles. Traditional methods are "ex vivo." This means immune cells are removed from the patient. They then undergo complex, costly lab manufacturing. This intricate process is time-consuming. It creates severe bottlenecks in treatment delivery. Patients often face long, anxious waits for their personalized therapy. Administration requires highly specialized academic medical centers. This critically limits patient access. Rural and underserved populations particularly struggle to obtain this advanced treatment.
Vyriad offers a fundamentally different path. Their approach is "in vivo." It modifies immune cells directly inside the patient's body. No external lab processing is needed. This completely changes the treatment paradigm. The lead candidate is VV169. It specifically targets relapsed or treatment-refractory multiple myeloma. This disease remains challenging for many patients.
VV169 employs a sophisticated lentiviral delivery platform. This platform, LV-169, acts as a precise genetic delivery system. It uses engineered G proteins. These ensure highly cell-specific targeting. T-cells within the patient receive new genetic instructions. They learn to recognize B-cell maturation antigen (BCMA). BCMA is a critical marker found on malignant multiple myeloma cells. The patient's own body effectively becomes its drug manufacturing facility. Potent killer cells generate rapidly. This happens in days, not weeks. The platform also minimizes immunogenicity. It simultaneously improves blood stability for the therapeutic agent.
VV169 is designed as a single intravenous administration. This eliminates the need for multiple hospital visits. It significantly simplifies logistics for patients and healthcare providers. The therapy is conceptualized as an "off-the-shelf" product. It is stored readily in a vial. This enables administration at local community clinics. No specialized manufacturing slot is required for each individual patient. This approach critically boosts scalability. It democratizes access to life-saving advanced immunotherapy. This could reach patients previously unable to travel or endure long hospital stays.
Preclinical data showcases VV169's strong potential. Vyriad presented compelling results at the ASH 2025 Annual Meeting. VV169 completely eliminated disseminated multiple myeloma. This remarkable outcome occurred in all humanized mouse models tested. Efficacy was consistently observed even at the lowest dose levels. This robust preclinical evidence provides a solid foundation for impending human trials. It builds confidence in the therapy's profound impact.
The substantial $85 million Series B financing round confirms strong investor belief. Harry Stine of Stine Seed Farms led this crucial funding round. Several prominent family offices also participated. This significant capital infusion directly supports VV169's imminent clinical debut. It validates Vyriad's innovative technology platform. The company's bold vision for targeted genetic therapies resonates strongly across the biotech investment landscape.
First-in-human Phase 1 clinical trials for VV169 are slated for 2026. This represents a critical milestone for Vyriad and the field of oncology. It will be the first opportunity to validate the in vivo delivery technology directly in patients. It will rigorously assess the in vivo CAR T candidate's safety and initial efficacy. Vyriad builds on years of extensive research. This includes groundbreaking work in cell-specific targeting and G-protein engineering. The company aims to fully realize the potential of truly effective CAR T therapies.
Vyriad’s ambition extends well beyond VV169. Its broader pipeline includes advanced oncolytic virotherapy programs. It also encompasses other innovative in vivo gene therapy applications. Groundbreaking gene-editing initiatives are actively underway. The company maintains ongoing corporate partnerships with major pharmaceutical entities. Regeneron Pharmaceuticals and Novartis are key collaborators. Phase 1-2 trials are currently progressing across multiple distinct cancer indications. This diversified, multi-pronged approach underscores Vyriad's profound commitment to transforming medicine.
Vyriad was co-founded by highly respected Mayo Clinic clinician-scientists. Dr. Stephen Russell and Dr. Kah-Whye Peng established the company. Their deep expertise underpins the rigorous scientific foundation. This strong academic and clinical foundation drives their mission. They focus relentlessly on delivering truly targeted genetic therapies to patients in need.
The in vivo CAR T revolution has truly begun. Vyriad leads this critical charge. VV169 promises a paradigm shift for multiple myeloma patients worldwide. It offers tangible hope for a more accessible, scalable, and ultimately more effective cancer treatment. This advancement could fundamentally redefine cancer therapy globally. The future of medicine looks profoundly different due to such innovations.
Vyriad secured substantial funding. The Rochester, Minnesota biotechnology firm closed an $85 million Series B round. This capital accelerates a radical shift in cancer treatment. Its focus: in vivo CAR T-cell therapy. This innovation aims to transform patient care for multiple myeloma.
Current CAR T therapies offer immense hope. They also present significant hurdles. Traditional methods are "ex vivo." This means immune cells are removed from the patient. They then undergo complex, costly lab manufacturing. This intricate process is time-consuming. It creates severe bottlenecks in treatment delivery. Patients often face long, anxious waits for their personalized therapy. Administration requires highly specialized academic medical centers. This critically limits patient access. Rural and underserved populations particularly struggle to obtain this advanced treatment.
Vyriad offers a fundamentally different path. Their approach is "in vivo." It modifies immune cells directly inside the patient's body. No external lab processing is needed. This completely changes the treatment paradigm. The lead candidate is VV169. It specifically targets relapsed or treatment-refractory multiple myeloma. This disease remains challenging for many patients.
VV169 employs a sophisticated lentiviral delivery platform. This platform, LV-169, acts as a precise genetic delivery system. It uses engineered G proteins. These ensure highly cell-specific targeting. T-cells within the patient receive new genetic instructions. They learn to recognize B-cell maturation antigen (BCMA). BCMA is a critical marker found on malignant multiple myeloma cells. The patient's own body effectively becomes its drug manufacturing facility. Potent killer cells generate rapidly. This happens in days, not weeks. The platform also minimizes immunogenicity. It simultaneously improves blood stability for the therapeutic agent.
VV169 is designed as a single intravenous administration. This eliminates the need for multiple hospital visits. It significantly simplifies logistics for patients and healthcare providers. The therapy is conceptualized as an "off-the-shelf" product. It is stored readily in a vial. This enables administration at local community clinics. No specialized manufacturing slot is required for each individual patient. This approach critically boosts scalability. It democratizes access to life-saving advanced immunotherapy. This could reach patients previously unable to travel or endure long hospital stays.
Preclinical data showcases VV169's strong potential. Vyriad presented compelling results at the ASH 2025 Annual Meeting. VV169 completely eliminated disseminated multiple myeloma. This remarkable outcome occurred in all humanized mouse models tested. Efficacy was consistently observed even at the lowest dose levels. This robust preclinical evidence provides a solid foundation for impending human trials. It builds confidence in the therapy's profound impact.
The substantial $85 million Series B financing round confirms strong investor belief. Harry Stine of Stine Seed Farms led this crucial funding round. Several prominent family offices also participated. This significant capital infusion directly supports VV169's imminent clinical debut. It validates Vyriad's innovative technology platform. The company's bold vision for targeted genetic therapies resonates strongly across the biotech investment landscape.
First-in-human Phase 1 clinical trials for VV169 are slated for 2026. This represents a critical milestone for Vyriad and the field of oncology. It will be the first opportunity to validate the in vivo delivery technology directly in patients. It will rigorously assess the in vivo CAR T candidate's safety and initial efficacy. Vyriad builds on years of extensive research. This includes groundbreaking work in cell-specific targeting and G-protein engineering. The company aims to fully realize the potential of truly effective CAR T therapies.
Vyriad’s ambition extends well beyond VV169. Its broader pipeline includes advanced oncolytic virotherapy programs. It also encompasses other innovative in vivo gene therapy applications. Groundbreaking gene-editing initiatives are actively underway. The company maintains ongoing corporate partnerships with major pharmaceutical entities. Regeneron Pharmaceuticals and Novartis are key collaborators. Phase 1-2 trials are currently progressing across multiple distinct cancer indications. This diversified, multi-pronged approach underscores Vyriad's profound commitment to transforming medicine.
Vyriad was co-founded by highly respected Mayo Clinic clinician-scientists. Dr. Stephen Russell and Dr. Kah-Whye Peng established the company. Their deep expertise underpins the rigorous scientific foundation. This strong academic and clinical foundation drives their mission. They focus relentlessly on delivering truly targeted genetic therapies to patients in need.
The in vivo CAR T revolution has truly begun. Vyriad leads this critical charge. VV169 promises a paradigm shift for multiple myeloma patients worldwide. It offers tangible hope for a more accessible, scalable, and ultimately more effective cancer treatment. This advancement could fundamentally redefine cancer therapy globally. The future of medicine looks profoundly different due to such innovations.